InMode Ltd. (NASDAQ:INMD) Receives Consensus Recommendation of “Hold” from Analysts

InMode Ltd. (NASDAQ:INMD) has received an average rating of “Hold” from the nine ratings firms that are currently covering the company, Marketbeat.com reports. One research analyst has rated the stock with a sell recommendation, seven have issued a hold recommendation and one has assigned a buy recommendation to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $16.80.

INMD has been the subject of several analyst reports. Robert W. Baird set a $17.00 target price on InMode in a report on Wednesday, February 11th. BTIG Research reiterated a “neutral” rating on shares of InMode in a report on Monday, January 26th. Weiss Ratings reissued a “sell (d+)” rating on shares of InMode in a research report on Thursday, January 22nd. Finally, Canaccord Genuity Group set a $15.00 price objective on shares of InMode and gave the company a “hold” rating in a report on Wednesday, December 17th.

Hedge Funds Weigh In On InMode

Institutional investors and hedge funds have recently bought and sold shares of the company. Leonteq Securities AG acquired a new stake in shares of InMode during the 4th quarter worth approximately $26,000. Quadrant Capital Group LLC lifted its holdings in InMode by 127.8% in the fourth quarter. Quadrant Capital Group LLC now owns 1,945 shares of the healthcare company’s stock valued at $29,000 after acquiring an additional 1,091 shares during the last quarter. Advisory Services Network LLC acquired a new position in InMode in the third quarter valued at approximately $37,000. Basepoint Wealth LLC purchased a new position in InMode in the fourth quarter worth approximately $39,000. Finally, Blue Trust Inc. increased its stake in InMode by 93.7% during the third quarter. Blue Trust Inc. now owns 2,861 shares of the healthcare company’s stock worth $43,000 after acquiring an additional 1,384 shares during the last quarter. 68.04% of the stock is currently owned by institutional investors and hedge funds.

InMode Price Performance

INMD opened at $13.75 on Thursday. The company’s 50 day simple moving average is $14.23 and its two-hundred day simple moving average is $14.57. InMode has a 1-year low of $12.72 and a 1-year high of $18.90. The firm has a market capitalization of $871.20 million, a price-to-earnings ratio of 9.55 and a beta of 2.18.

InMode (NASDAQ:INMD) last posted its quarterly earnings results on Tuesday, February 10th. The healthcare company reported $0.46 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.42 by $0.04. InMode had a return on equity of 14.52% and a net margin of 25.33%.The business had revenue of $103.85 million during the quarter, compared to analyst estimates of $104.64 million. During the same period in the prior year, the business earned $0.42 earnings per share. The business’s revenue was up 6.1% compared to the same quarter last year. On average, equities analysts anticipate that InMode will post 1.75 earnings per share for the current fiscal year.

InMode Company Profile

InMode Ltd. (NASDAQ:INMD) is a medical technology company headquartered in Israel that develops, manufactures and markets devices for aesthetic and medical treatments. The company specializes in energy-based technologies, primarily radiofrequency platforms, designed to deliver minimally-invasive and non-invasive procedures.

InMode’s product portfolio encompasses a range of modular systems targeting body contouring, facial rejuvenation, skin tightening and other cosmetic applications. Key offerings include devices built on proprietary radiofrequency and radiofrequency-assisted lipolysis, enabling physicians to perform treatments such as tissue coagulation, skin resurfacing and subdermal volumizing with reduced downtime.

The company distributes its technologies through direct sales operations and distribution partners, serving medical professionals across multiple geographies including North America, Europe, Asia Pacific and Latin America.